Find a Clinical Trial

Print this page
ProtocolTrial Name and Objective
130909

Psychological Interventions for Gynecologic Cancer

Very little is known in the psycho-oncology literature about why psychological interventions are effective or for how long these interventions exert an impact. Given many cancer patients experience recurrence and/or progression, it is important to know whether our relatively brief interventions facilitate how patients cope with this most-feared medical event. From a theoretical perspective, the study will advance our understanding of the mechanisms for change for two common treatment approaches, supportive and cognitive behavioral therapies.
Primary Objective: To evaluate the efficacy of CCI, SC, and Usual Care (UC) on patients? long-term general and cancer-specific psychological adaptation, concerns about recurrence/progression, and quality of life, and to determine whether intervention effects are moderated by disease recurrence.
Secondary Objective: To evaluate the cognitive, social, emotional, and behavioral processes which mediate CCI and SC?s effects on patients? long-term general and cancer-specific psychological adaptation, concerns about recurrence/progression, and quality of life.
(More)


001310

Revisiting the Methods to Calculate Carboplatin Dose in Women with Gynecologic Cancers A Retrospective Chart Review

The purpose of this study is to evaluate the precision and accuracy of creatinine clearance estimation by the Cockcroft-Gault, Jelliffe, and Wright formula and determine which formula is the best substitute for the gold standard of GFR estimation for the purpose of carboplatin dosing in a gynecologic oncology population.
(More)


131222

Dietary Inflammatory Index and Ovarian Cancer Risk

Our study aims to evaluate the role of a new dietary inflammatory index in predicting ovarian cancer risk. We will also compare results with those obtained with the Healthy Eating Index.
(More)


051304

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

To evaluate preliminary signals of potential anti-tumor activity of MK-3475
in subjects with a given a histopathologic type of PD-L1 positive advanced solid tumor based on RECIST 1.1 as determined by the investigator in specific tumor indications
(More)